Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma sa  - certolizumab pegol - artrite, rewmatika - immunosoppressanti - rewmatika arthritiscimzia, flimkien ma ' methotrexate (mtx), huwa indikat għall -: - trattament ta moderata sa severa, artrite rewmatojde attiva (ra) f'pazjenti adulti meta r-rispons għall li jimmodifikaw il-marda mediċini anti-rewmatiċi (dmards), inkluż mtx, kienet inadegwata. cimzia jista 'jingħata bħala monoterapija f'kaz ta' intolleranza għal mtx jew fejn kura kontinwa b'mtx mhux inappropriatethe trattament ta severa, attiva u progressiva f'adulti li ma kinux ittrattati qabel ma ' mtx jew dmards oħra. cimzia kien muri li jnaqqas ir-rata ta 'progressjoni tal-ħsara fil-ġogi kif imkejjel permezz ta' x-ray, u li jtejjeb il-funzjoni fiżika, meta jingħata flimkien ma ' mtx. assjali aksjali cimzia huwa indikat għall-kura ta ' pazjenti adulti b'attiva severa assjali aksjali, li jinkludu:l-ankylosing spondylitis (as)adulti b'ankylosing spondylitis severa u attiva li kellhom rispons mhux adegwat għal, jew li huma intolleranti għal mediċini anti-infjammatorji mhux sterojdi (nsaids). assjali aksjali mingħajr evidenza

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - marda ta 'crohn - immunosoppressanti - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia jista 'jingħata bħala monoterapija f'kaz ta' intolleranza għal methotrexate jew meta trattamenti fit-tul b'methotrexate mhux adattat. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - chicken - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - chicken - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international b.v. - herpesvirus tad-dundjan rikombinanti ħajjin assoċjat miegħu (strain hvt / ilt-138), li jesprimi l-glycoproteins gd u gi tal-virus tal-laryngotracheitis infettiva - immunoloġiċi għall-aves, vaċċini virali Ħajjin - chicken - għall-immunizzazzjoni attiva ta ' wieħed mill-flieles biex tnaqqas l-imwiet, sinjali kliniċi u leżjonijiet tal-minħabba li infezzjoni bl-infettiva tat-tjur laryngotracheitis (ilt) u l-virus tal-marda ta'marek (md) tal-virus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunoloġiċi għall-għasafar - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

grunenthal gmbh - allopurinol, lesinurad - gotta - preparazzjonijiet antigout - duzallo huwa indikat fl-adulti għat-trattament ta'l-iperuriċemija fil-gotta pazjenti li ma kisbux-mira tal-uric acid fis-serum livelli b'doża adegwata ta ' allopurinol waħdu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - febuxostat - gotta - preparazzjonijiet antigout - 80 mg saħħa:it-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat fl-adulti. 120 mg saħħa:adenuric huwa indikat għat-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat għall-prevenzjoni u t-trattament ta'l-iperuriċemija f'pazjenti adulti li għaddejjin minn kimoterapija għal tumuri malinni ematoloġiċi fil-intermedjarju u għoli tar-riskju tas-sindrome tal-lisi tat-tumur (tls). adenuric huwa indikat fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - l-arsenic trioxide - lewkimja, promyelocytic, akuta - aġenti antineoplastiċi - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. ir-rata ta ' rispons ta oħra akuti lewkimja miloġenja-sottotipi għall-arsenic trioxide ma ġew eżaminati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - capecitabine - neoplażmi kolorettali - aġenti antineoplastiċi - capecitabine medac huwa indikat għall-adjuvant trattament tal-pazjenti wara l-kirurġija fl-istadju tal-iii (dukes ta' stadju-c) tal-colon cancer. capecitabine medac huwa indikat għat-trattament tal-kanċer metastatiku tal-kolorektum. capecitabine medac huwa indikat għall-kura preferita tal-kanċer gastriku avvanzat flimkien ma ' reġim ibbażat fuq il -. capecitabine medac flimkien ma 'docetaxel huwa indikat għall-kura ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. capecitabine medac huwa wkoll indikat bħala monoterapija għall-kura ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' taxanes u ta 'kors ta' kimoterapija li fihom jew li għalihom l-aktar anthracycline ma tkunx indikata t-terapija.